Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126240203 | 12624020 | 3 | F | 20160726 | 20160919 | 20160804 | 20160927 | EXP | US-ASTRAZENECA-2016SE82351 | ASTRAZENECA | 24212.00 | DY | M | Y | 0.00000 | 20160927 | MD | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126240203 | 12624020 | 1 | PS | DAPAGLIFLOZIN | DAPAGLIFLOZIN | 1 | Oral | 36600 | MG | Y | 202293 | 100 | MG | TABLET | QD | ||||
| 126240203 | 12624020 | 2 | SS | DAPAGLIFLOZIN | DAPAGLIFLOZIN | 1 | Oral | 36600 | MG | Y | 202293 | 100 | MG | TABLET | QD | ||||
| 126240203 | 12624020 | 3 | SS | LISINOPRIL. | LISINOPRIL | 1 | Oral | Y | 0 | ||||||||||
| 126240203 | 12624020 | 4 | SS | ALDACTONE | SPIRONOLACTONE | 1 | Oral | Y | 0 | ||||||||||
| 126240203 | 12624020 | 5 | C | HYDROCHLOROTHIAZIDE. | HYDROCHLOROTHIAZIDE | 1 | Oral | 0 | |||||||||||
| 126240203 | 12624020 | 6 | C | AMLODIPINE | AMLODIPINE BESYLATE | 1 | Oral | 0 | |||||||||||
| 126240203 | 12624020 | 7 | C | VITAMIN D3 | CHOLECALCIFEROL | 1 | Oral | 0 | |||||||||||
| 126240203 | 12624020 | 8 | C | CALCIUM | CALCIUM | 1 | Oral | 0 | |||||||||||
| 126240203 | 12624020 | 9 | C | ROPINIROLE. | ROPINIROLE | 1 | Oral | 0 | |||||||||||
| 126240203 | 12624020 | 10 | C | VITAMIN B | VITAMIN B | 1 | Oral | 0 | |||||||||||
| 126240203 | 12624020 | 11 | C | METFORMIN | METFORMIN HYDROCHLORIDE | 1 | Oral | 0 | 2000 | MG | QD | ||||||||
| 126240203 | 12624020 | 12 | C | GLIPIZIDE. | GLIPIZIDE | 1 | Oral | 0 | 10 | MG | QD | ||||||||
| 126240203 | 12624020 | 13 | C | GLUCOCIL | 2 | Oral | 0 | 2 | DF | TABLET | QD | ||||||||
| 126240203 | 12624020 | 14 | C | ATORVASTATIN | ATORVASTATIN | 1 | Oral | 0 | 20 | MG | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126240203 | 12624020 | 1 | Type 2 diabetes mellitus |
| 126240203 | 12624020 | 2 | Type 2 diabetes mellitus |
| 126240203 | 12624020 | 3 | Hypertension |
| 126240203 | 12624020 | 4 | Hypertension |
| 126240203 | 12624020 | 5 | Hypertension |
| 126240203 | 12624020 | 6 | Hypertension |
| 126240203 | 12624020 | 7 | Supplementation therapy |
| 126240203 | 12624020 | 8 | Supplementation therapy |
| 126240203 | 12624020 | 9 | Neuropathy peripheral |
| 126240203 | 12624020 | 10 | Supplementation therapy |
| 126240203 | 12624020 | 11 | Diabetes mellitus |
| 126240203 | 12624020 | 12 | Diabetes mellitus |
| 126240203 | 12624020 | 13 | Diabetes mellitus |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126240203 | 12624020 | HO |
| 126240203 | 12624020 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126240203 | 12624020 | Hyperkalaemia |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126240203 | 12624020 | 1 | 20140703 | 20150528 | 0 | |
| 126240203 | 12624020 | 2 | 20160621 | 20160726 | 0 | |
| 126240203 | 12624020 | 3 | 20160727 | 0 | ||
| 126240203 | 12624020 | 4 | 20160226 | 20160727 | 0 | |
| 126240203 | 12624020 | 5 | 20160727 | 0 | ||
| 126240203 | 12624020 | 10 | 20141001 | 0 | ||
| 126240203 | 12624020 | 11 | 20160727 | 0 | ||
| 126240203 | 12624020 | 13 | 20150801 | 0 |